Venture
Capital for Nanotechnology and Microsystems
Fellow
Shareholders:
Historically, we have prepared an
annual letter to shareholders and published it in our Annual Report on Form
10-K. We will continue this tradition in 2010. Beginning
this year, we will also write an additional letter to shareholders at the
beginning of each year to update shareholders on recent events and to provide
information on the company and our portfolio.
We are
looking forward to 2010. The IPO market began to rebound in the
second half of 2009. From our non-deal road shows and discussions
with bankers and analysts, it is evident that if macro-economic conditions
continue to improve into 2010, institutional investors will be searching for new
growth opportunities. As we look at our portfolio, management
believes that we may have opportunities for exit in 2010 and 2011 if the IPO
window stays open. The lead paragraph of an article titled, “Comeback
Time for Venture IPOs,” on page C3 in Monday, February 1, 2010’s Wall Street
Journal states “This could be the year that venture-backed companies start to
get their IPO groove back.” According to the article, “VentureSource
counts 33 venture-backed companies on file for IPOs with the Securities and
Exchange Commission…” The same article quotes a general partner at
Highland Capital Partners as saying that “I think acquisition activity will be
at least, if not more, active than the IPO market” for venture capital-backed
firms.
We also
believe that the current conditions in the markets create many opportunities to
use our cash to invest in companies. We began 2010 with $56 million in cash and
U.S. Treasury obligations. At a time when venture capital is scarce
and when many venture capital firms cannot raise additional funds, we believe
this capital provides opportunities to invest in promising companies at low
valuations. In addition to having a portfolio of companies in which
we have priority investment rights, we have a robust deal flow in which to
deploy this cash, both in privately held and publicly traded
companies.
We have
been looking to invest in micro-capitalization publicly traded
companies. We have made an investment in one such company, Orthovita,
during the second half of 2009. In 2010, we will continue to look for
opportunities to invest in publicly traded companies. Additionally,
we have been looking to invest in private companies with the following
characteristics: we believe they will require less than $15 to $20 million of
cumulative invested capital each to get to exit; we believe we can own between
five and 25 percent of the company while initially investing less than $1
million; and, we believe the company can generate revenue or another form of
commercial validation using the initial investment made by
investors. We have invested in two such companies since the third
quarter of 2009.
We do
face certain risks in 2010. First, the IPO market is still not
conducive to small IPOs and companies with market capitalizations below $500
million. To be successful, we will need to find ways to get some of
our companies to IPOs in less time, with less money invested, at market
capitalizations below $500 million and with IPO raises of less than $50
million. This effort will require drawing upon our relationships with
bankers and analysts that have strong track records in this space and
identifying institutional investors willing to invest in the growth
opportunities of micro-cap public companies. We have managed many of
our companies such that $100 to $500 million market cap IPOs would allow us to
make meaningful investment returns. Additionally, we believe our
portfolio includes companies that could potentially grow to be billion dollar
companies, so that many of the structural issues facing small public companies
will be less germane.
Second,
we will need to continue to manage our portfolio in an environment where venture
capitalists and venture capital-backed companies continue to struggle to raise
capital. We need to find ways to protect our ownership interests and,
in some cases, increase our ownership positions in our best companies during
this unusual period. We have already taken steps towards this end in
NeoPhotonics by making an additional investment during the fourth quarter of
2009 and exercising warrants in the first quarter of 2010.
At
September 30, 2009, our top 10 holdings by value represented 68 percent of the
value of our venture capital portfolio. In 2010, we believe only
three of these top 10 holdings will require additional financing, and one of
these companies is in the process of securing additional
financing. Additionally, in 2009, the number of companies with
greater than $10 million in revenue or sales was seven, up from six in
2008. In the aggregate, our companies generated more revenue and
sales in 2009 than in 2008.
Positive
recent announcements related to some of our larger holdings included the
following:
|
·
|
On
January 22, 2010, Nanosys announced the signing of a commercial agreement
with LG Innotek.
|
|
·
|
On
January 13, 2010, Bridgelux announced it had raised an additional $50
million in Series D financing and appointed Bill Watkins as
CEO.
|
|
·
|
On
January 8, 2010, Innovalight announced it had raised an additional $18
million in Series D financing.
|
|
·
|
On
January 7, 2010, Ensemble announced its third strategic alliance, the
first with Pfizer Inc. The alliance included upfront and
research payments, development milestones, and royalties based on future
worldwide sales of any drugs emerging from the
alliance.
|
|
·
|
On
December 4, 2009, Solazyme announced it had received $21.8 million from
the U.S. government for a pilot plant to produce algae-based
oil.
|
Currently,
more than one of our companies are in the planning stages for a possible
acquisition or IPO. Subject to market conditions, these events could
provide liquidity in these companies for Harris & Harris Group by
2011.
We expect
to file our Annual Report on Form 10-K with the Securities and Exchange
Commission and post it on our website by March 16, 2010. We will
follow that as usual with an annual letter to shareholders that will focus on
our strategy and our portfolio. For the first time, we will then host
a quarterly call with shareholders on March 19, 2010. We will use
this call to answer questions on our financials, discuss our strategy for the
coming years, and bring investors up to date on our portfolio companies, to the
extent we are permitted under the confidentiality agreements we have signed with
each company.
On May 7,
2010, we also plan to host our second “Meet the Portfolio” Day in New York City
focusing on the companies in our “Nanotech for Healthcare”SM
portfolio. The CEOs from seven portfolio companies will present their
companies and be available to answer questions from institutional investors,
analysts, bankers and our shareholders.
In
closing, let us reiterate that our number one priority heading into 2010 is to
look for opportunities to monetize our portfolio companies at appropriate
valuations. We have invested in quality nanotechnology
companies. We have managed that portfolio through turbulent
times. Now, we must look to exiting these investments and realizing
gains on our investments at the appropriate times. Our second
priority is to continue to deploy our cash resources in exciting publicly traded
and privately held companies at appropriate valuations. We believe we
can pursue both of these goals in a way that will work to the benefit of the
shareholders of Harris & Harris Group.
We hope
you will join us on our first quarterly call on Friday, March 19,
2010.
|
|
Douglas
W. Jamison
|
Daniel
B. Wolfe
|
Chairman,
Chief Executive Officer
|
President,
Chief Operating Officer,
|
and
Managing Director
|
Chief
Financial Officer and Managing
Director
|
|
|
Michael
A. Janse
|
Alexei
A. Andreev
|
Executive
Vice President and
|
Executive
Vice President and
|
Managing
Director
|
Managing
Director
|
February
3, 2010